Business Context and Reporting Period
The provided filing is an unaudited Form 10-Q for the quarter ended June 30, 2016, filed August 15, 2016. The filing identifies the registrant as Zeta Acquisition Corp. II, not Whitehawk Therapeutics, Inc.; this entity mismatch should be verified.
Zeta Acquisition Corp. II was a Delaware blank-check and shell company formed to identify and complete a business combination. It had no operating business, generated no revenue since inception, and had not identified or discussed a potential business combination.
Financial Metrics
| Metric | Three Months Ended June 30 | Six Months Ended June 30 |
|---|---|---|
| Revenue | $0 | $0 |
| General and administrative expense | $5,103 | $9,065 |
| Interest expense | $2,543 | $4,937 |
| Net loss | $(7,646) | $(14,002) |
| Net loss per share | $(0.00) | $(0.00) |
- Cash and cash equivalents were $20,279 at June 30, 2016, versus $18,529 at December 31, 2015.
- Current liabilities were $220,762, including $170,000 of stockholder notes payable, $37,373 of accrued interest, $10,189 of accounts payable, and $3,200 of accrued expenses.
- Stockholders’ deficit was $200,483 at June 30, 2016, compared with $186,481 at December 31, 2015.
- Six-month operating cash flow was $(8,250), compared with $(15,168) in the prior-year period. Financing provided $10,000 through stockholder notes, compared with $20,000 in the prior-year period, resulting in a $1,750 net increase in cash.
- Profit margins are not meaningful because the company had no revenue and reported operating and net losses.
- The stockholder notes are unsecured, bear interest at 6%, and are due on demand. Accrued interest was $37,373 at June 30, 2016.
Material Changes Versus Prior Comparable Period
- Three-month net loss increased to $7,646 from $7,272, primarily due to higher interest expense; general and administrative expense was unchanged at $5,103.
- Six-month net loss increased to $14,002 from $13,087. Interest expense increased to $4,937 from $4,022, while general and administrative expense remained $9,065.
- Operating cash use improved to $8,250 from $15,168, but stockholder financing declined to $10,000 from $20,000.
- Cash increased to $20,279 from $10,095 at June 30, 2015, but liabilities remained substantially greater than assets.
Outlook, Risks, Contingencies, and Unusual Items
- Management planned to continue searching for a suitable acquisition candidate and expected to incur reporting and acquisition-investigation costs.
- Management stated that the company may require additional stockholder, management, investor, or other financing and could not assure that funding would be available or that cash requirements could be met for the next twelve months.
- The financial statements disclose substantial going-concern uncertainty. Continued operations depend on future financing, profitable operations, or completion of a suitable business combination.
- The company had generated a cumulative net loss of $250,483 since inception and depended on related parties for continued funding.
- The company reported no material legal proceedings, no unregistered equity sales, no defaults upon senior securities, and no material off-balance-sheet arrangements.
- Deferred tax assets of approximately $85,100 were fully offset by a valuation allowance because realization was uncertain.
- The company used office space and equipment provided by an officer and director at no cost under a month-to-month arrangement; management considered the value immaterial.
- Management concluded that disclosure controls and procedures were effective as of June 30, 2016, with no material changes in internal control over financial reporting during the quarter.
Investor Verification Priorities
- Verify whether this filing belongs to Whitehawk Therapeutics, Inc. or to Zeta Acquisition Corp. II, as the source text identifies only the latter.
- Assess the going-concern risk, including cash of $20,279 versus current liabilities of $220,762.
- Confirm the terms, demand status, related-party nature, and repayment prospects of the $170,000 stockholder notes and accrued interest.
- Determine whether any business combination discussions or financing occurred after June 30, 2016.
- Verify the company’s continued shell-company status, absence of revenue, and dependence on additional financing.